Rapt Therapeutics, Inc. is a US-based pharmaceutical company with a focus on ESG-based biopharmaceuticals. Specializing in oncology and inflammatory diseases, the company is working on developing oral small-molecule therapies to meet unmet patient needs. Their pipeline includes products like FLX475 and RPT193, targeting specific cell types in tumors and inflamed tissues. With a medium ESG risk rating score of 26.6, Rapt Therapeutics is committed to sustainable and responsible governance practices.